要点
- Carmat has obtained data proving the effectiveness of its artificial heart technology.
- The reimbursement approval (remboursement) process from the French Social Security may begin.
- This approval will change patients' access to the device and the company's commercial roadmap.
French artificial heart specialist Carmat has obtained data proving its technologies work. This development could lead to the company obtaining reimbursement approval from the French Social Security (Assurance Maladie) for its products.
Carmat, a pioneer in artificial heart development, has crossed a commercial and medical threshold by gathering clinical evidence. If reimbursement approval comes, patients' access to these life-saving devices will be significantly eased.
リアクション
この記事について質問
回答はこの記事のみからAIが生成します。
よくある質問
- In which field is Carmat a specialized company?
- Carmat is a French medical technology company developing total artificial heart systems.
- What does reimbursement approval (remboursement) mean?
- It means the French health insurance (Assurance Maladie) covers the cost of the device, meaning patients can obtain the device for free or at a very low cost.
- When will this development affect patients?
- The article does not give a specific date; it states the approval process has begun, but the timing of the official decision has not been disclosed.
関連記事
健康